Injection Intervals in Real-world Neovascular Age-related Macular Degeneration (nAMD) Patients Switching to Brolucizumab With at Least 12 Months of Follow-up

Inclusion Criteria

• •Patients with a diagnosis of nAMD.
• •Patients were on a previous anti-VEGF therapy and then switched to brolucizumab.
• •Patients remained on brolucizumab for at least 12 months.
• •Patients had exactly 360 days or more of follow-up after first brolucizumab injection.
• •For BRO cohort only: Patients received at least three injections of brolucizumab during study period.
• •For ALT cohort only: Patients received at least two injections of brolucizumab and one injection of another anti-VEGF during the study period.